Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 6/20 | 0.51 |
| ▸ | CYSLTR1 | Q9Y271 | 6/20 | 0.51 |
| ▸ | MET | P08581 | 2/20 | 0.47 |
| ▸ | XDH | P47989 | 1/20 | 0.46 |
| ▸ | CYSLTR2 | Q9NS75 | 2/20 | 0.46 |
| ▸ | SGMS2 | Q8NHU3 | 1/20 | 0.46 |
| ▸ | PPARG | P37231 | 1/20 | 0.45 |
| ▸ | PPARD | Q03181 | 1/20 | 0.45 |
| ▸ | PPARA | Q07869 | 1/20 | 0.45 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2888217 | 0.97 | CYSLTR1 (0.51) | GRM2CYSLTR1METXDHCYSLTR2 | |
| SCHEMBL2893623 | 0.92 | GRM2 (0.52) | GRM2CYSLTR1XDHCYSLTR2 | |
| SCHEMBL3177661 | 0.89 | CYSLTR1 (0.52) | GRM2CYSLTR1CYSLTR2SGMS2PPARG | |
| SCHEMBL10751332 | 0.88 | CYSLTR1 (0.58) | GRM2CYSLTR1CYSLTR2PPARGPPARD | |
| SCHEMBL2891955 | 0.88 | CYSLTR1 (0.63) | GRM2CYSLTR1CYSLTR2 | |
| SCHEMBL2888457 | 0.87 | CYSLTR1 (0.53) | GRM2CYSLTR1CYSLTR2PPARGPPARD | |
| SCHEMBL2895824 | 0.86 | GRM2 (0.63) | GRM2CYSLTR1 | |
| SCHEMBL2894689 | 0.85 | RXFP1 (0.46) | GRM2CYSLTR1CYSLTR2PPARGPPARD | |
| SCHEMBL2892010 | 0.85 | CYSLTR1 (0.53) | GRM2CYSLTR1CYSLTR2 | |
| SCHEMBL3157692 | 0.85 | CYSLTR1 (0.51) | GRM2CYSLTR1CYSLTR2PPARGPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7678794-B2 | Potentiators of glutamate receptors | ELI LILLY AND COMPANY (US) | 2010-03-16 | — | — | US | disclosed |
| EP-1817296-B1 | POTENTIATORS OF GLUTAMATE RECEPTORS | LILLY CO ELI (US) | 2009-11-04 | — | — | EP | disclosed |
| US-20080004321-A1 | 3-{[4-(4-acetyl-3-hydroxy-2-propylphenoxymethyl)-phenyl]-(S)-hydroxymethyl}-benzoic acid; anxiolytic, neuroleptic agent and antidepressant as glutamate receptor agonist; antiinflammatory agent as leukotriene receptor agonist; | ELI LILLY AND COMPANY | 2008-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080004321-A1 | 3-{[4-(4-acetyl-3-hydroxy-2-propylphenoxymethyl)-phenyl]-(S)-hydroxymethyl}-benzoic acid; anxiolytic, neuroleptic agent and antidepressant as glutamate receptor agonist; antiinflammatory agent as leukotriene receptor agonist; | LTB4R, LTB4R2, CYSLTR1 | GRM2 15/4885CYSLTR1 3/4885MET 2716/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.